Hairy Cell Leukemia and HCL-Like Disorders: Diagnosis and TreatmentLeuc閙ie �Tricholeucocytes et Autres Prolif閞ations �Cellules Chevelues: Diagnostic et Traitement

Maître, Elsa; Troussard, Xavier

doi:10.32604/oncologie.2022.021490

Cited by 3 publications

(1 citation statement)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data indicates that within 2 years of diagnosis, over 80% of patients experience recurrence, Am J Cancer Res 2024;14 (1):145-154 with only 7% to 12.7% surviving for at least 5 years [9]. Immunochemotherapy currently serves as the first-line standard of treatment for various diseases, including glioma and hairy cell leukemia (HCL-V) [10]. As bone marrow is frequently involved at the diagnosis and relapse stages of stage 4 NB, analyzing the characteristics of bone marrow relapse in HR-NB could provide valuable insights influencing future HR-NB strategies [11,12].…”

Section: Introductionmentioning

confidence: 99%

Bone marrow relapse in stage 4 neuroblastoma of children in Shanghai

2024

Am J Cancer Res

View full text Add to dashboard Cite

Objective: To characterize the epidemiological, clinical, and molecular features of bone marrow relapse in high-risk neuroblastoma (HR-NB) and to identify potential prognostic indicators and therapeutic approaches for this specific subset within the Shanghai pediatric oncology landscape. Methods: A retrospective study was conducted on 256 patients diagnosed with stage 4 neuroblastoma at two major pediatric hospitals in Shanghai, China, between 2008 and 2018. Patient data was collected, including demographic information, treatment regimens, and outcomes. Kaplan-Meier method and log-rank test were used for overall survival (OS) and event-free survival (EFS) analysis. Results: The study revealed that bone marrow relapse affected 50.78% of patients, making it the most frequent relapse site. Patients with bone marrow involvement at diagnosis face an increased risk of subsequent bone marrow relapse. Age over 18 months, multiple metastatic sites, and the absence of autologous stem cell transplantation (ASCT) were identified as significant risk factors for bone marrow relapse. The 3-year OS and EFS rates of patients with bone marrow relapse were 32.5% and 32.5%, respectively. Patients receiving ASCT demonstrated significantly higher survival rates. The lack of ASCT at diagnosis was significantly correlated with lower survival rates, particularly in patients experiencing bone marrow relapse. Conclusion: The study provides valuable insights into the challenges posed by bone marrow relapse in the setting of high-risk neuroblastoma. It emphasizes the need for tailored therapeutic approaches to improve outcomes, potentially involving novel targeted agents and immunotherapies. The study underscores the poor prognosis associated with bone marrow relapse in HR-NB and the urgent need for further research to optimize risk stratification and therapeutic strategies, including prospective investigation and the integration of advanced molecular profiling techniques.

show abstract

Section: Introductionmentioning

confidence: 99%

Bone marrow relapse in stage 4 neuroblastoma of children in Shanghai

2024

Am J Cancer Res

View full text Add to dashboard Cite

show abstract

The role of ADC value and Ki-67 index in predicting the response to neoadjuvant chemotherapy in advanced stages of olfactory neuroblastoma

Wang

Zhang

et al. 2022

BJR

View full text Add to dashboard Cite

Objectives: To investigate the efficacy of pretreatment ADC and Ki-67 index in the prediction of the response to neoadjuvant chemotherapy (NACT) in advanced olfactory neuroblastoma (ONB) patients. Methods: A total of 21 advanced ONB patients (mean 43.48 years ± 14.26; range 25–69 years; 13 men and 8 women) with diffusion weighted imaging (DWI) before NACT between June 2015 and October 2021 were retrospectively analyzed. Patients were categorized into responders and non-responders according to RECIST 1.1 after two cycles of NACT. The clinical data, ADCmean value and Ki-67 index were analyzed. Results: Kadish stage, ADCmean value and Ki-67 index showed statistical significance between responders and non-responders. Patients with Kadish C stage were more likely to respond to platinum-based NACT (p = 0.035). Patients with the lower ADCmean value showed response to NACT (p = 0.002) and the cutoff point was 1.04 × 10−3 mm2/s. Patients with the higher Ki-67 index showed response to NACT (p = 0.003) and the cutoff point was 17.5%. Predictive performance of Ki-67 index and ADCmean value showed no significance between responders and non-responders (p = 0.865). A significant negative correlation was found between ADCmean value and Ki-67 index (r = −0.539, p = 0.038). Conclusions: The pretreatment ADCmean value, Ki-67 index and Kadish stage have the potential to predict the response to NACT in advanced ONB patients. Advances in knowledge: This is the first study that investigated the feasibility of DWI in predicting the response to NACT in ONB patients, and showed that Kadish stage, pretreatment ADCmean and Ki-67 index may play an important role in the prediction.

show abstract

Meta-analysis on the efficacy of allogeneic hematopoietic stem cell transplantation to treat malignant lymphoma

Zhao,

Guo,

Zheng

et al. 2024

Open Life Sciences

View full text Add to dashboard Cite

The goal of the study involved the comparison of clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) in the treatment of malignant lymphoma (ML). The effectiveness of allo-HSCT versus auto-HSCT in the treatment of ML was compared by searching EMBASE, PubMed, Web of Science, and the Cochrane Library for relevant studies. The confidence intervals (CI) and odds ratio (OR) of the article’s outcomes were described by a forest plot. Finally, 972 patients in seven articles were included. Overall survival (OS) did not differ significantly between allo-HSCT and auto-HSCT groups (OR = 0.87, 95% CI: 0.66–1.14, P = 0.31). Furthermore, there was no significant difference in adverse reactions (AR) between the two groups (OR = 1.35, 95% CI: 0.81–2.24, P = 0.25). We observed a significant difference in progression-free survival (PFS) between the two groups (OR = 4.14, 95% CI: 2.93–5.35, P < 0.01). There was no evidence of publication bias in this meta-analysis. The incidence of OS and AR differ significantly between allo-HSCT and auto-HSCT, but the PFS was longer in ML patients who received allo-HSCT.

show abstract

Hairy Cell Leukemia and HCL-Like Disorders: Diagnosis and TreatmentLeuc閙ie �Tricholeucocytes et Autres Prolif閞ations �Cellules Chevelues: Diagnostic et Traitement

Cited by 3 publications

References 147 publications

Bone marrow relapse in stage 4 neuroblastoma of children in Shanghai

Bone marrow relapse in stage 4 neuroblastoma of children in Shanghai

The role of ADC value and Ki-67 index in predicting the response to neoadjuvant chemotherapy in advanced stages of olfactory neuroblastoma

Meta-analysis on the efficacy of allogeneic hematopoietic stem cell transplantation to treat malignant lymphoma

Contact Info

Product

Resources

About